Prof Max Topp speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about a dose escalation trial in patients with relapsed and refractory B-cell non-hodgkin lymphoma using REGN1979 - an anti-CD20 x anti-CD3 bispecific antibody.
He explains that the aim of the study was to determine safety, tolerability and occurrence of dose limiting toxicities - reporting that it was well tolerated and that no dose limiting or neurological toxicities were observed. The maximum tolerated dose was not reached.
Looking forward, Prof Topp suggests that next steps will be focused on the responses of subgroups.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.